- Actinium to present on Tuesday, October 17^th at 3 PM PT

NEW YORK, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that it will present at the BIO Investor Forum being held on October 16-17^th at the Westin St. Francis Hotel in San Francisco, California. Details for Actinium’s presentation are below:

Date: Tuesday, October 17, 2017
Time: 3:00 PM PT
Room: Elizabethan C

Members of Actinium's management team will be available for one-on-one meetings with conference attendees. To arrange a meeting with management, please contact Steve O'Loughlin, Actinium's Principal Financial Officer, at soloughlin@actiniumpharma.com or utilize the conference partnering system https://login.partnering.bio.org.

About BIO Investor Forum

The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2018.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant (“BMT”). BMT is often the only potential cure for patients with blood-borne cancers but current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Iomab-B aims to enable a faster and less toxic preparation of patients seeking BMT, potentially leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (“AML”) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. More information available at www.actiniumpharma.com and Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc. 
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Vice President, Finance and Corporate Development
soloughlin@actiniumpharma.com

Investor Relations
Marek Ciszewski, J.D.
949.574.3860
ATNM@liolios.com

Released October 16, 2017